WEB On July 20 2023 Idorsia sold its operating businesses in the Asia Pacific ex-China region to Sosei. WEB Allschwil Switzerland October 24 2023 IDIA today announced its financial results. IDIA today announced its financial results for the first half of 2023. WEB On July 21 2023 Idorsia announced that it has launched a cost reduction initiative with the target to reduce cash-burn at. WEB Allschwil Switzerland September 6 2023 IDIA today announced that it has entered. IDIA today announced its financial results for the first half of 2023. WEB Idorsia announces financial results for the first quarter 2023 QUVIVIQ now the leading branded. IDIA today announced its financial results for the first quarter of 2023..
Globenewswire
WEB On July 20 2023 Idorsia sold its operating businesses in the Asia Pacific ex-China region to Sosei. WEB Allschwil Switzerland October 24 2023 IDIA today announced its financial results. IDIA today announced its financial results for the first half of 2023. WEB On July 21 2023 Idorsia announced that it has launched a cost reduction initiative with the target to reduce cash-burn at. WEB Allschwil Switzerland September 6 2023 IDIA today announced that it has entered. IDIA today announced its financial results for the first half of 2023. WEB Idorsia announces financial results for the first quarter 2023 QUVIVIQ now the leading branded. IDIA today announced its financial results for the first quarter of 2023..
IDIA today announced that it has entered into agreements for a significant global research and development collaboration with Viatris Inc. IDIA today announced its financial results for the first nine months of 2023 Transaction with Sosei Heptares hereafter referred as the. Aprocitentan Approval Is A Vital News 22 2024 1149 AM ET Idorsia Ltd IDRSF Stock 1 Comment. WEB Idorsia Media release US FDA approves Idorsias once-daily TRYVIO aprocitentan the first and only endothelin receptor antagonist for the treatment of high blood pressure not. IDIA today announced positive top-line results of PRECISION the Phase 3 study investigating aprocitentan Idorsias dual endothelin receptor antagonist for the treatment..
WEB Allschwil Switzerland March 18 2024 IDIA today announced that it has successfully closed the transaction with Viatris Inc. IDIA today announced its financial results for the first nine months of 2023 Transaction with Sosei Heptares hereafter referred as the. WEB Financial highlights as reported Net revenue 9M 2023 at CHF 131 million US GAAP operating expenses 9M 2023 at CHF 275 million and non-GAAP operating expenses 9M 2023 at. WEB Sale leaseback Idorsia entered into an agreement generating gross proceeds of CHF 164 million Company is committed to manage operating. WEB Switzerland-based Idorsia has burnt through cash in recent years racking up losses of 375 million Swiss francs 426 million in the first half of last year alone as it advanced a broad..
**Idorsia Reports Financial Performance and Business Updates** **Allschwil, Switzerland – October 24, 2023** Idorsia Pharmaceuticals Ltd. (IDIA) today announced its financial results for the first half of 2023. **Financial Highlights** * Revenue reported at CHF 97.0 million * Operating loss of CHF 102.2 million * Net cash position of CHF 1.2 billion **Business Updates** * **Sale of Asia Pacific ex-China Businesses:** On July 20, 2023, Idorsia completed the sale of its operating businesses in the Asia Pacific ex-China region to Sosei. * **Cost Reduction Initiative:** On July 21, 2023, Idorsia announced a cost reduction initiative aimed at reducing cash-burn. * **Strategic Partnership with Sosei:** On September 6, 2023, Idorsia announced a strategic partnership with Sosei to advance the development and commercialization of novel therapies. **Financial Results for First Quarter 2023** Idorsia also announced its financial results for the first quarter of 2023. **Financial Highlights (Q1 2023)** * Revenue reported at CHF 45.6 million * Operating loss of CHF 52.1 million * Net cash position of CHF 1.3 billion **Product Updates** * QUVIVIQ remains the leading branded therapy for Huntington's disease. * Idorsia continues to explore the development of new therapies in its pipeline. "We are pleased to report our financial results for the first half of 2023," said Jean-Paul Clozel, MD, CEO of Idorsia. "We believe our strategic initiatives, including the sale of our Asia Pacific ex-China businesses and the cost reduction initiative, will position us for future growth and profitability."
Delco Today
Comments